

March 14, 2023

Naari Pharma Pvt. Ltd.: Update on Material Event

Summary of rating action

Instrument*	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Outstanding
Long-term – Fund-based – Term loan	34.60	34.60	[ICRA]BB-(Stable)
Long-term – Fund-based – Working capital limits	40.00	40.00	
Short-term – Fund-based/ Non-fund based – Working capital limits (sublimit)	(30.00)	(30.00)	[ICRA]A4
Total	74.60	74.60	

*Instrument details are provided in Annexure I

Rationale

On March 02, 2023, ICRA was informed that Tenshi Life Sciences Private Limited (Tenshi Life or the company), the parent of Naari Pharma Private Limited (Naari) has received the final order from National Company Law Tribunal (NCLT) pertaining to the company's amalgamation with Tenshi Pharmaceuticals Private Limited (Tenshi Pharma).

Considering the business linkages between Naari and Tenshi Life and financial support provided by Tenshi Life, as and when required, ICRA had taken implicit support from Tenshi Life for arriving at Naari's ratings.

ICRA takes note of the aforementioned update on amalgamation of Tenshi Life with Tenshi Pharma. ICRA will continue to engage with the company to evaluate the impact of the aforementioned update on its credit profile. Further, ICRA will continue to monitor these developments and take appropriate rating action as and when more clarity emerges.

Please refer to the following link for the previous detailed rationale that captures the key rating drivers and their description, the liquidity position, rating sensitivities and key financial indicators: [Click here](#)

Analytical approach

Analytical Approach	Comments
Applicable Rating Methodologies	Corporate Credit Rating Methodology ICRA's Rating methodology for Pharmaceuticals Rating approach – implicit parent or group support
Parent/Group Support	Tenshi Life holds 42% stake (fully diluted) in Naari. Considering the business linkages and financial support provided by Tenshi Life, as and when required, ICRA has taken implicit support from Tenshi Life for arriving at Naari's ratings.
Consolidation/Standalone	The rating is based on the standalone financial statements of the rated entity.

About the company

Naari was incorporated as Indo Phyto Chemicals Private Limited on February 23, 1978. The company manufactures active pharmaceutical ingredients (APIs), fermentation intermediaries and Finished Dosage Forms (FDF) products in the female healthcare domain. Naari is present in the female healthcare formulations business across more than 45 countries. It has issued Cumulative Convertible Preference Shares (CCPS) to Ascent Capital, wherein the company has received Rs. 125 crore cumulatively in FY2020 and FY2021. Naari's API and intermediate manufacturing facility is located at Kashipur, India. Naari's R&D for APIs and intermediates is located at this site with infrastructure for the development and scale up of chemical and fermentation processes. Naari's FDF manufacturing facility is located at Rudrapur, India, and is involved in the development

and manufacturing of hormones with capabilities across tablets and soft gel capsules (under development). The R&D facility is recognised by Department of Scientific and Industrial Research (DSIR).

Key financial indicators

Naari Standalone	FY2021	FY2022
Operating income (Rs. crore)	91.3	105.4
PAT (Rs. crore)	-0.2	-0.8
OPBDITA/OI (%)	6.3%	6.6%
PAT/OI (%)	-0.3%	-0.7%
Total outside liabilities/Tangible net worth (times)	1.0	1.2
Total debt/OPBDITA (times)*	9.6	13.4
Interest coverage (times)	0.9	1.2

PAT: Profit after Tax; OPBDITA: Operating Profit before Depreciation, Interest, Taxes and Amortisation; All Amounts as per ICRA calculations; ; * total debt including OCRPS

Status of non-cooperation with previous CRA: Not applicable

Any other information: None

Rating history for past three years

Current rating (FY2023)								Chronology of rating history for the past 3 years	
Instrument	Type	Amount Rated (Rs. crore)	Amount outstanding as of Sep 30, 2022 (Rs. crore)	Date & Rating in FY2023			Date & Rating in FY2022	Date & Rating in FY2021	Date & Rating in FY2020
				Mar 14, 2023	Dec 29, 2022	Jul 28, 2022			
1 Term loan	Long term	34.60	18.40	[ICRA]BB-(Stable)	[ICRA]BB-(Stable)	[ICRA]BB+(CE) (Stable)	[ICRA]BBB-(CE) (Negative)	-	[ICRA]BBB-(CE) (Negative)
2 Fund based – Working capital limits	Long term	40.00	--	[ICRA]BB-(Stable)	[ICRA]BB-(Stable)	[ICRA]BB+(CE) (Stable)	[ICRA]BBB-(CE) (Negative)	-	[ICRA]BBB-(CE) (Negative)
3 Fund based/ non-fund based*	Short term	(30.00)	--	[ICRA]A4	[ICRA]A4	[ICRA]A4+ (CE)	[ICRA]A3(CE)	-	[ICRA]A3(CE)

Amount in Rs. Crore; *Sublimit of long-term fund based

Complexity level of the rated instruments

Instrument	Complexity Indicator
Term loan	Simple
Fund based working capital limits	Simple
Fund based/ Non-fund based working capital	Very Simple

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's

credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional, or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: [Click Here](#)

Annexure I: Instrument details

ISIN No	Instrument Name	Date of Issuance	Coupon Rate	Maturity Date	Amount Rated (Rs. crore)	Current Rating and Outlook
NA	Term loans	FY2020	9.55% - 11.5%	FY2023 – FY2024	34.60	[ICRA]BB- (Stable)
NA	Fund based – Working capital limits	FY2021	9.55%	--	40.00	[ICRA]BB- (Stable)
NA	Fund based/ non-fund based	FY2021	9.55%	--	(30.00)	[ICRA]A4

Source: Company; Note: Amounts in Rs. crore

[Please click here to view details of lender-wise facilities rated by ICRA](#)

Annexure II: List of entities considered for consolidated analysis – Not applicable

ANALYST CONTACTS

Shamsher Dewan

+91 124 4545 5328

shamsherd@icraindia.com

Kinjal Shah

+91 22 6114 3442

kinjal.shah@icraindia.com

Mythri Macherla

+91 80 4332 6407

mythri.macherla@icraindia.com

Seetha Pillai

+91 80 4332 6411

seetha.pillai@icraindia.com

RELATIONSHIP CONTACT

Jayanta Chatterjee

+91 80 4332 6401

jayantac@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani

Tel: +91 124 4545 860

communications@icraindia.com

Helpline for business queries

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

About ICRA Limited:

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited




Registered Office

B-710, Statesman House, 148, Barakhamba Road, New Delhi-110001

Tel: +91 11 23357940-45



Branches



© Copyright, 2023 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.